home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9601.ZIP
/
M9610164.TXT
< prev
next >
Wrap
Text File
|
1996-01-30
|
2KB
|
34 lines
Document 0164
DOCN M9610164
TI [Multidrug-resistant tuberculosis. Epidemiology, treatment, prevention
and diagnostic research]
DT 9601
AU Perronne C; de Truchis P; Service des maladies infectieuses et
tropicales, hopital; Raymond-Poincare, Garches, France.
SO Rev Med Interne. 1995;16(7):547-52. Unique Identifier : AIDSLINE
MED/96008894
AB The recent augmentation of the prevalence of multidrug resistant (MDR)
tuberculosis is related to the high incidence of tuberculosis in HIV
infected people, especially in those with low social status and no
medical care; several nosocomial epidemics of MDR tuberculosis were
observed in American and European institutions where HIV-infected
persons were hospitalized; these MDR tuberculosis were associated with a
high mortality-rate and frequent nosocomial transmission to
immunocompromised contacts and care workers. The rapid institution of an
adequate treatment with ancient antituberculosis agents (cycloserin,
capreomycin, aminoglycosides) and/or new drugs (rifabutine, ofloxacin,
sparfloxacin, etc) is necessary to avoid mortality and to diminish
transmission. Prevention of MDR tuberculosis transmission is very
important: patient isolation, adequate and prolonged therapy, better
detection of resistance with gene-amplification methods (PCR) which are
under investigation.
DE Comorbidity Cross Infection/EPIDEMIOLOGY English Abstract
France/EPIDEMIOLOGY Human HIV Infections/EPIDEMIOLOGY Polymerase
Chain Reaction *Tuberculosis,
Multidrug-Resistant/DIAGNOSIS/EPIDEMIOLOGY/THERAPY JOURNAL ARTICLE
REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).